Dr. Monica Verma, MD

Dr. Verma practices at Tennessee Oncology in Chattanooga, Tennessee.

Dr. Verma's NPI, 1518948124, was assigned on November 10, 2005. Dr. Verma holds Georgia license 050277.

Dr. Verma's primary practice is Tennessee Oncology, at 605 Glenwood Dr, Chattanooga, TN 37404 in Hamilton County. The practice phone is (615) 329-0570.

Dr. Verma's primary practice is Tennessee Oncology in Chattanooga, Tennessee. Dr. Verma is also affiliated with Erlanger Baroness Hospital. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Verma to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Verma practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Verma's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Verma is licensed in Georgia.

CMS data shows 46,836 Medicare services from Dr. Verma across 38 procedure codes in 2024, for 455 Medicare patients. Medicare paid $479,894 for them.

CMS counts 455 Medicare patients who saw Dr. Verma in 2024. The largest group is 75 to 84, with 197 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Verma's median patient age at 69, with 64% women.

In 2024, Dr. Verma wrote 1,466 Medicare Part D claims for 206 patients. 72% of them were for generic drugs. CMS names the drug for 1,199 of them, across 37 drugs with 11 or more claims each, at $3,938,770 in total drug cost. In 2023, CMS named 1,172 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Verma for performance year 2024, reported as part of a group. Dr. Verma accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Verma as offering telehealth.

Dmand AI links 10 papers to Dr. Verma, published from 2015 to 2024. 2022 was the busiest year, with 2. Dr. Verma has published most often in Clin Lab. Dr. Verma's most frequent co-authors are Mahmut Akgul, Khaleel Ibrahim Al-Obaidy, MD and Mahul B. Amin, MD.

CMS Open Payments shows 598 general payments to Dr. Verma from 67 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 76% of the total. Janssen Pharmaceuticals, Inc paid the most, $2,091.